Systemic Amyloidosis due to Low-Grade Lymphoma.
Abstract Lymphoma-related amyloidosis is a rare entity. Systemic AL amyloidosis is generally caused by an underlying plasma cell clone in the bone marrow with an intact monoclonal immunoglobulin G (IgG) or IgA protein. The rarity of the lymphoma-related amyloidosis makes the generation of data in randomized trials and the determination of the optimal treatment almost impossible. Therefore, treatment recommendations discussed here are based on either retrospective or small prospective trials of single centers. PMID: 33099421 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 28, 2020 Category: Cancer & Oncology Authors: Wechalekar AD, Chakraborty R, Lentzsch S Tags: Hematol Oncol Clin North Am Source Type: research

High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management.
PMID: 33074750 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 19, 2020 Category: Cancer & Oncology Authors: Jain P, Dreyling M, Seymour JF, Wang M Tags: J Clin Oncol Source Type: research

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
CONCLUSIONS: Combined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation. PMID: 33055173 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 14, 2020 Category: Cancer & Oncology Authors: Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA Tags: Clin Cancer Res Source Type: research

Physical Activity in People with Multiple Myeloma: Associated Factors and Exercise Program Preferences.
This study explored PA among people with MM, including differences by treatment stage, symptoms and demographics, and programming preferences. Overall, 126 people with MM (77% response rate) completed the survey. Pre-diagnosis, 25.4% were sufficiently active, with 12.0% remaining active after treatment. Respondents who were physically active pre-diagnosis were 46.7 times (95% confidence intervals CI: 2.03, 1072.1) more likely to meet PA guidelines following an MM diagnosis compared to people not meeting guidelines pre-diagnosis. Experiencing MM symptoms and receiving PA advice from healthcare professionals were not associa...
Source: Clinical Lymphoma and Myeloma - October 13, 2020 Category: Cancer & Oncology Authors: Nicol JL, Woodrow C, Burton NW, Mollee P, Nicol AJ, Hill MM, Skinner TL Tags: J Clin Med Source Type: research

Blastoid Mantle Cell Lymphoma.
This article presents a comprehensive review on blastoid MCL in 2020. PMID: 32861288 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 1, 2020 Category: Cancer & Oncology Authors: Jain P, Wang M Tags: Hematol Oncol Clin North Am Source Type: research

Message from the Chairmen.
PMID: 32862847 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Lonial S, Kantarjian H, Freireich EJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Update on CML-Like Disorders.
Abstract Chronic myeloid leukemia (CML) is defined for many years as BCR-ABL1 positive disease, but older publications refer to a poor prognosis, clinically heterogeneous entity termed 'BCR-ABL1 negative CML' constituting about 5% of CML cases. Apart from very rare CML cases with cytogenetically cryptic, atypical variant BCR-ABL1 fusions that had been inadvertently missed during the diagnostic work up, most of these cases would now be classified as a subtype of myelodysplastic/myeloproliferative neoplasm (MDS/MPN), such as atypical CML (aCML), chronic myelomonocytic leukemia (CMML), or chronic neutrophilic leukemi...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Cross NCP Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Next Questions - Classical Hodgkin Lymphoma (cHL).
PMID: 32862849 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Straus DJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management of Asparaginase Toxicity in AYAs with ALL.
PMID: 32862850 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Schmiegelow K, Rank CU Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Young Woman with Thrombocytosis.
Abstract The diagnostic approach to thrombocytosis involves consideration of reactive, hereditary, and neoplastic causes. Once reactive causes of thrombocytosis, such as iron deficiency, infections, solid tumors, and other obvious causes such as post-splenectomy thrombocytosis, have been ruled out, the focus shifts to myeloid malignancies, such as chronic myeloid leukemia (CML), the classic Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), primary myelofibrosis (PMF), polycythemia vera (PV), myelodysplastic syndrome (MDS) with isolated deletion 5q and the r...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Bose P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Case Presentation: A Young Man with Polycythemia Vera and Fatigue.
PMID: 32862852 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Hobbs G Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis.
Abstract In patients with myelofibrosis (MF), allogeneic stem cell transplantation (SCT) is a curative treatment, but does entail risk of treatment-related mortality (TRM). Furthermore, a minority of patients cured of myelofibrosis are at risk of chronic graft-versus-host disease (GvHD) that may impair their quality of life. It is also pertinent to note that transplant early in the disease course results in better transplant outcome than transplant late in the disease course.1 Thus, the survival benefit of SCT needs to be weighed against early transplant related mortality (TRM) and morbidity, as well as impaired q...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Joseph J, Popat U Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Pitfalls in Assessing Response to Treatment in MDS.
PMID: 32862854 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Platzbecker U Tags: Clin Lymphoma Myeloma Leuk Source Type: research

BTK Inhibitors and Chemoimmunotherapy for CLL.
PMID: 32862855 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Thompson P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Venetoclax in AML: Where We Are and Where We Are Headed.
Abstract The developmental path for venetoclax in acute myeloid leukemia (AML) has been rapid and stands in stark contrast to the incremental progress that has characterized the field in previous decades. For perspective, on December 31, 2013, the first AML patient was enrolled into a study using venetoclax; 59 months later, on November 21, 2018, venetoclax received accelerated approval by the FDA for use in AML. In June 2020, Dr. DiNardo presented the results of the required confirmatory study at the European Hematology Association meeting, showing that venetoclax with azacitidine resulted in a superior response ...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Pollyea DA Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Hereditary Hematologic Malignancies.
PMID: 32862857 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: DiNardo C Tags: Clin Lymphoma Myeloma Leuk Source Type: research

IDH Inhibition.
PMID: 32862858 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: de Botton S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management of Older Patients with Acute Lymphocytic Leukemia - Novel Treatment Strategies.
PMID: 32862859 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Jabbour E, Kantarjian H Tags: Clin Lymphoma Myeloma Leuk Source Type: research

How I Approach the Patient Who Has MRD or Relapse After Transplant.
PMID: 32862860 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Muffly L Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment of Early (Limited)-Stage DLBCL.
PMID: 32862861 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Kumar A, Persky DO Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Burkitt Lymphoma - Subtypes, Pathogenesis, and Treatment Strategies.
Abstract Burkitt's lymphoma (BL) is a rare and highly aggressive Non-Hodgkin lymphoma (NHL) with a germinal center phenotype, a nearly universal myc oncogene translocation to an enhancer element and a proliferation index greater than 95%.1 Bcl-2 is not expressed as opposed to double-hit or triple-hit lymphoma. Genetic mutations and aberrancy involving the phosphatidylcholine 3-kinase and cyclin-dependent kinase pathways are also involved.2-5 Rarely patients present with stage I disease and others are considered as high risk if greater than stage I or with elevated LDH or masses greater than 10 cm. PMID: 32862...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Noy A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Waldenstr öm Macroglobulinemia - 2020 Update on Management and Future Directions.
Waldenström Macroglobulinemia - 2020 Update on Management and Future Directions. Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S39-S41 Authors: Thomas SK PMID: 32862863 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Thomas SK Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Bone Diseases and Supportive Care.
PMID: 32862864 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Hillengass J, Merz M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future.
PMID: 32862865 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Luskin MR, DeAngelo DJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Who Should Receive an Allogeneic Transplant in First Complete Remission?
era J Abstract The decision to incorporate allogeneic hematopoietic stem cell transplant (allo-HSCT) into front-line therapy in adult acute lymphoblastic leukemia (ALL) should be primarily guided by measurable residual disease (MRD) status and the ALL regimen utilized. While there is no doubt that allo-HSCT benefits patients with poor MRD response after induction or consolidation, the indication of allo-HSCT in cases of good MRD clearance is not clear. As targeted immunotherapies result in high MRD-negative CR rates, early incorporation of these therapies may also prove valuable in reducing the need for HCT in the...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Ribera JM, Genescà E, Ribera J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

FLT3 Inhibition in Acute Myeloid Leukemia.
Abstract Mutations in the FLT3 receptor tyrosine kinase are the most frequently found mutations in acute myeloid leukemia (AML). Patients with FLT3 internal tandem duplication (ITD) mutations have poor prognoses. The approved FLT3 tyrosine kinase inhibitors (TKIs) midostaurin and gilteritinib improve survival in AML with FLT3 mutations. Multiple other FLT3 inhibitors are in clinical development. Patients frequently relapse after response to FLT3 inhibitors and the optimal use of FLT3 inhibitors in the upfront, relapse, and maintenance settings remain to be established. We will discuss the biology of FLT3, approved...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Smith CC Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care.
PMID: 32862868 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Short NJ, Jabbour E Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Is Less More? Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL.
PMID: 32862869 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Chiaretti S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Immunotherapy for T-Cell ALL and T-Cell NHL.
PMID: 32862870 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: DiPersio JF, Staser K, Cooper M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

New Approaches for Anemia in MDS.
PMID: 32862871 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Platzbecker U Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Harnessing Apoptosis in AML.
Abstract The treatment landscape for AML has grown significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in AML contin...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Saxena K, DiNardo C, Daver N, Konopleva M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

The Problem of TP53-Mutant MDS/AML.
PMID: 32862873 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Sallman DA Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Targeting CD123 in AML.
Abstract An ideal cell surface target for therapy in leukemia would be: tumor-specific (not expressed on normal cells) or at least enriched on tumor cells, necessary for tumor but not for normal cell survival, internalized efficiently (if the surface-targeted agent is conjugated to chemotherapy or a toxin molecule), and recycled rapidly to the cell surface. While a single target that meets all of these criteria has not yet been discovered in AML, CD123 has emerged as an attractive candidate.1 The first-in-class CD123-targeting agent, tagraxofusp-erzs (SL-401) was approved in 2018 for patients with blastic plasmacy...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Lane AA Tags: Clin Lymphoma Myeloma Leuk Source Type: research

New Therapies in Development for Myelofibrosis.
PMID: 32862875 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Chifotides HT, Verstovsek S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Mechanisms of Response and Resistance to AML Therapies.
PMID: 32862876 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Stoilova B, Moore R, Metzner M, Zheng Z, Konopleva M, DiNardo C, Vyas P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Improving Survival After Transplant in Myelofibrosis.
PMID: 32862877 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Joseph J, Popat U Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Case Presentation - Thrombosis in PV: How to Predict and How to Reduce Risk.
PMID: 32862878 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Hobbs G Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma - Moving Toward a Personalized Approach.
Abstract CASE VIGNETTE: A 75-year-old male undergoes an evaluation for progressively worsening fatigue with associated shortness of breath. He also reports back pain worse at night, which does not resolve with acetaminophen. He is retired, but over the past 2 months he is unable to garden or perform household chores. Due to his pain and fatigue, he has limited his activity. He currently takes 9 prescription medications for chronic medical conditions, which include diabetes mellitus with neuropathy, hypertension, hyperlipidemia, and COPD. Initial evaluation reveals anemia (Hgb 9.0 g/dl last known normal was 2 years...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Grant SJ, Lipe B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment.
PMID: 32862880 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Gupta S, Maude SL, O'Brien MM, Rau RE, McNeer JL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Frontline Therapy for Fit MM Patients Should Include an Antibody.
PMID: 32862881 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Voorhees P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

What is Fitness in the Era of Targeted Agents?
Abstract Chronic lymphocytic leukaemia (CLL) is a disease of the elderly, most frequently diagnosed among people aged 65-74 years.1 Aging brings about a reduction of the functional reserves of organs and systems, translating into a reduced tolerance to treatment. Although aging and frailty are two concepts that have always gone hand-in-hand, chronological age alone is not a sufficient measure of fitness. Some elderly patients have no comorbidity and are functionally independent; others struggle with comorbidities, polypharmacy, functional dependence, or cognition and mood problems. Patients of the same age can hav...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Tedeschi A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment of Newly Diagnosed Classical Hodgkin Lymphoma.
PMID: 32862883 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Straus DJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Pathology and Pathogenesis of T-Cell Lymphoma.
Abstract Peripheral T cell lymphomas (PTCLs) are a heterogeneous and often clinically aggressive group of neoplasms derived from mature post-thymic T lymphocytes. These neoplasms are rare and usually diagnostically challenging. Our understanding of the pathogenesis of PTCL is increasing and this improved knowledge is leading us to better molecular characterization, more objective diagnostic criteria, more effective risk assessment, and potentially to better treatments for these neoplasms. PMID: 32862884 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Vega F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Advances in CAR T-Cell Therapy for Aggressive B-NHL.
PMID: 32862885 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Riedell PA Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management of Relapsed Mantle Cell Lymphoma.
PMID: 32862886 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Cohen JB Tags: Clin Lymphoma Myeloma Leuk Source Type: research

The expressions of MUM-1 and Bcl-6 in ALK-negative systemic anaplastic large cell lymphoma with skin involvement and primary cutaneous anaplastic large cell lymphoma.
CONCLUSION: Although the cutaneous manifestations of ALK-negative systemic ALCL and PC-ALCL are similar, the prognoses and treatment approaches are considerably different. Our results indicate that MUM-1 expression is commonly expressed in both types of ALCL, but Bcl-6 is less commonly expressed in PC-ALCL cases and systemic ALCL with skin involvement cases. PMID: 32782689 [PubMed] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 13, 2020 Category: Cancer & Oncology Authors: Cho YR, Seo JW, Oh SY, Pak MK, Kim KH Tags: Int J Clin Exp Pathol Source Type: research

Sj ögren Syndrome and Cancer.
This article discusses the accumulating data on various malignancies described in primary Sjögren syndrome, highlighting non-Hodgkin lymphoma and thyroid, multiple myeloma, and skin cancers. These reported associations may have clinical implications in daily practice and contribute to understanding of both autoimmunity and cancer. PMID: 32631601 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 9, 2020 Category: Cancer & Oncology Authors: Igoe A, Merjanah S, Scofield RH Tags: Rheum Dis Clin North Am Source Type: research

Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Abstract Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Although median overall survival rates exceed 12 years with rituximab, follicular lymphoma remains largely incurable. The growing understanding of the molecular drivers of lymphomagenesis and the tumor microenvironment have led to novel therapies. Prognostic markers have identified a subset of patients with chemoresistant and/or refractory disease-associated poor outcomes. We identify the patients with follicular lymphoma in need of novel therapies, describe the drivers of lymphomagenesis and importance of the tumor microenvironmen...
Source: Clinical Lymphoma and Myeloma - June 27, 2020 Category: Cancer & Oncology Authors: Chin CK, Nastoupil LJ Tags: Hematol Oncol Clin North Am Source Type: research

Retraction Notice.
Authors: PMID: 32553269 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 20, 2020 Category: Cancer & Oncology Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Bone marrow particle enrichment analysis for the laboratory diagnosis of multiple myeloma: A case study.
CONCLUSIONS: Bone marrow particle enrichment analysis may be applied to overcome the problems caused by hemodilution of bone marrow aspirates and to improve the rate of tumor cell detection. The application of this method for the diagnosis of hematological disorders should be explored further. PMID: 32548852 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 15, 2020 Category: Cancer & Oncology Authors: Zhang C, Zhang Y Tags: J Clin Lab Anal Source Type: research